share_log

UPLOAD: Others

UPLOAD: Others

UPLOAD:其他
美股sec公告 ·  05/14 13:05
Moomoo AI 已提取核心訊息
NeuroSense Therapeutics Ltd., a company specializing in neurological treatments, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-1, filed on May 10, 2024, will not undergo review. The SEC's communication, dated May 14, 2024, was addressed to Alon Ben-Noon, CEO of NeuroSense Therapeutics, and was sent from the Division of Corporation Finance, Office of Life Sciences. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC provided contact information for Tim Buchmiller.
NeuroSense Therapeutics Ltd., a company specializing in neurological treatments, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-1, filed on May 10, 2024, will not undergo review. The SEC's communication, dated May 14, 2024, was addressed to Alon Ben-Noon, CEO of NeuroSense Therapeutics, and was sent from the Division of Corporation Finance, Office of Life Sciences. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC provided contact information for Tim Buchmiller.
美國證券交易委員會(SEC)已通知專注於神經治療的公司NeuroSense Therapeutics Ltd.,其提交於2024年5月10日的F-1表格註冊聲明將不經過審核。SEC的通信日期爲2024年5月14日,信件是寄給NeuroSense Therapeutics的CEO Alon Ben-Noon的,發件人是公司金融部生命科學辦公室。SEC的信件還涉及460和461條規則,這些規則與請求加速註冊過程有關。此外,SEC提醒公司及其管理層,無論SEC的審核水平如何或缺乏審核,他們都有責任確保其披露信息的準確性和充分性。如需進一步查詢,SEC提供了Tim Buchmiller的聯繫信息。
美國證券交易委員會(SEC)已通知專注於神經治療的公司NeuroSense Therapeutics Ltd.,其提交於2024年5月10日的F-1表格註冊聲明將不經過審核。SEC的通信日期爲2024年5月14日,信件是寄給NeuroSense Therapeutics的CEO Alon Ben-Noon的,發件人是公司金融部生命科學辦公室。SEC的信件還涉及460和461條規則,這些規則與請求加速註冊過程有關。此外,SEC提醒公司及其管理層,無論SEC的審核水平如何或缺乏審核,他們都有責任確保其披露信息的準確性和充分性。如需進一步查詢,SEC提供了Tim Buchmiller的聯繫信息。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息